Dermata Therapeutics, Inc. (DRMA)
| Market Cap | 3.96M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -12.29M |
| Shares Out | 5.43M |
| EPS (ttm) | -8.03 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 44,851 |
| Open | 0.7200 |
| Previous Close | 0.7100 |
| Day's Range | 0.7051 - 0.7200 |
| 52-Week Range | 0.7000 - 6.1700 |
| Beta | 0.58 |
| Analysts | Strong Buy |
| Price Target | 6.00 (+745.07%) |
| Earnings Date | May 14, 2025 |
About DRMA
Dermata Therapeutics, Inc., a late-stage medical dermatology company, focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical skin diseases and aesthetic applications. Its lead product candidate is XYNGARI, which is in Phase 3 clinical studies for the treatment of moderate-to-severe acne, as well as completed Phase 1b proof of concept (POC) trial for mild-to-moderate psoriasis. The company is also developing DMT410 that has completed Phase 1b POC trials for the treatment of axillary... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to one analyst, the rating for DRMA stock is "Strong Buy" and the 12-month stock price forecast is $6.0.
News
Dermata's XYNGARI(TM) Phase 3 Trial Hits Statistically Significant Difference at 4 Weeks
- Dermata previously announced XYNGARI(TM) produced highly statistically significant topline data for all primary endpoints at week 12 in Phase 3 trial - - Additional data analysis revealed that XYNGA...
Dermata Therapeutics Announces Exercise of Warrants for $6.2 Million in Gross Proceeds Priced At-the-Market Under Nasdaq Rules
SAN DIEGO, CA / ACCESS Newswire / March 27, 2025 / Dermata Therapeutics, Inc. (NASDAQ:DRMA)(NASDAQ:DRMAW) ("Dermata," or the "Company"), a late-stage biotechnology company focused on the treatment of ...
Nano-Cap Dermata Therapeutics Unveils Positive Data From Once Weekly Drug Study For Acne
Dermata Therapeutics, Inc. DRMA stock is trading higher on Thursday.
Dermata Therapeutics Shares Surge on Positive Acne Treatment Study
Dermata Therapeutics shares jumped more than 50% in early trading Thursday after the biotechnology company said its Xyngari once-weekly, topical product candidate for the treatment of moderate-to-seve...
BREAKING: Dermata's XYNGARI™ Phase 3 Trial Topline Data Meets All Primary Endpoints
- XYNGARI™ achieved its primary endpoints, demonstrating highly statistically significant and clinically meaningful improvement in acne - - XYNGARI™ is the first once-weekly topical product candidate ...
Dermata Therapeutics Provides Corporate Update and Reports Year End 2024 Financial Results
- Dermata expects to announce topline results from its XYNGARI™ Phase 3 Spongilla Treatment of Acne Research (STAR-1) clinical trial by end of March 2025 - - The Company recently entered into a Clinic...
Dermata Announces that Last Patient Completes Last Visit in Pivotal XYNGARI™ Phase 3 STAR-1 Clinical Trial for Acne
- STAR-1 topline results expected by the end of March 2025 - - Over 30 million acne patients seek treatment in the U.S. each year - - XYNGARI™ Phase 3 STAR-1 trial enrolled 520 patients with moderate-...
Dermata Receives Notice of Acceptance of Australian Patent Application for Topical Botulinum Toxin Treatment for Hyperhidrosis
- This would be Dermata's second patent for DMT410, if issued, using its Spongilla technology to topically deliver botulinum toxin for hyperhidrosis - - The Company recently entered into a Clinical Tr...
Dermata to Present on BioPub on January 31, 2025
- Dermata's Chief Executive Officer and Chief Development Officer will provide a corporate update and answer live questions from the biotech investment community - SAN DIEGO, CA / ACCESS Newswire / Ja...
Dermata Expands Patent Portfolio with Issuance of New U.S. Patent for Next-Generation Acne Treatment
- This is Dermata's first issued U.S. patent for XYNGARI™, which uses its Spongilla technology to topically treat acne - - Dermata expects to announce topline results from its STAR-1 Phase 3 XYNGARI™ ...
Dermata Therapeutics Announces Closing of $2.55 Million Private Placement Priced At-The-Market Under Nasdaq Rules
SAN DIEGO, CA / ACCESS Newswire / January 23, 2025 / Dermata Therapeutics, Inc. (NASDAQ:DRMA)(NASDAQ:DRMAW) ("Dermata," or the "Company"), a late-stage biotechnology company focused on the treatment o...
Dermata Therapeutics Announces $2.55 Million Private Placement Priced At-The-Market Under Nasdaq Rules
Dermata Therapeutics, Inc. (NASDAQ:DRMA)(NASDAQ:DRMAW) ("Dermata," or the "Company"), a late-stage biotechnology company focused on the treatment of medical and aesthetic skin diseases and conditions,...
Dermata and Revance Enter Clinical Trial Collaboration Agreement for the Topical Application of Xyngari(TM) with Daxxify(R)
The Companies intend to first initiate a Phase 2a clinical trial evaluating Xyngari™ with Daxxify® to treat primary axillary hyperhidrosis - If successful, the Companies may explore clinical developme...
Dermata Receives Approval from FDA for the Proprietary Name Xyngari(TM)
- Xyngari (formerly DMT310) is currently being studied in Phase 3 for the treatment of acne, with topline results from the first Phase 3 STAR-1 study expected in March 2025 - SAN DIEGO, CA / ACCESSWIR...
Dermata Receives Notice of Allowance for New U.S. Patent for DMT310 for the Treatment of Acne
- This is Dermata's first allowed U.S. patent application for DMT310, using its Spongilla technology to topically treat acne - - Dermata recently completed enrollment in its DMT310 Phase 3 STAR-1 stud...
Dermata Completes Enrollment in First Pivotal DMT310 Phase 3 STAR-1 Clinical Trial for Acne
SAN DIEGO, CA / ACCESSWIRE / December 3, 2024 / Dermata Therapeutics, Inc. (NASDAQ:DRMA)(NASDAQ:DRMAW) ("Dermata" or the "Company"), a late-stage biotechnology company focusing on the treatment of med...
Dermata Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results
- Dermata nears completion of enrollment in its DMT310 Phase 3 Spongilla Treatment of Acne Research (STAR-1) clinical trial - - Dermata continues discussions with potential botulinum toxin partners fo...
Dermata Therapeutics to Present at the Life Sciences Investor Forum on Thursday, November 14, 2024
– Dermata Therapeutics invites individual and institutional investors, as well as advisors and analysts, to attend online at VirtualInvestorConferences.com – – Dermata Therapeutics invites individual ...
Dermata Therapeutics to Participate in the 2024 Maxim Healthcare Virtual Summit on Tuesday, October 15, 2024
SAN DIEGO, CA / ACCESSWIRE / October 8, 2024 / Dermata Therapeutics, Inc. (NASDAQ:DRMA)(NASDAQ:DRMAW) ("Dermata" or the "Company"), a late-stage biotechnology company focusing on the treatment of medi...
Dermata Therapeutics Announces Closing of $3.5 Million Private Placement Priced At-The-Market Under Nasdaq Rules
Dermata raises approximately $7.8 million in gross proceeds since May 2024 - expected to fund its operations into the second quarter of 2025 SAN DIEGO, CA / ACCESSWIRE / September 17, 2024 / Dermata T...
Dermata Therapeutics Announces $3.5 Million Private Placement Priced At-The-Market Under Nasdaq Rules
SAN DIEGO, CA / ACCESSWIRE / September 16, 2024 / Dermata Therapeutics, Inc. (NASDAQ:DRMA)(NASDAQ:DRMAW) ("Dermata," or the "Company"), a late-stage biotechnology company focused on the treatment of m...
Dermata Therapeutics Announces Participation at the H.C. Wainwright 26th Annual Global Investment Conference September 9-11, 2024
SAN DIEGO, CA / ACCESSWIRE / September 5, 2024 / Dermata Therapeutics, Inc. (Nasdaq:DRMA; DRMAW) ("Dermata" or the "Company"), a late-stage biotechnology company focusing on the treatment of medical a...
Dermata Therapeutics Provides Corporate Update and Reports Second Quarter 2024 Financial Results
- DMT310 Phase 3 Spongilla Treatment of Acne Research (STAR-1) clinical trial has enrolled over 50% of patients - Dermata continues discussions with potential botulinum toxin partners for DMT410 - Rai...
Dermata Announces Achievement of 50% Enrollment in Pivotal DMT310 Phase 3 STAR-1 Clinical Trial for Acne
- STAR-1 topline results expected in first quarter of 2025 - - About 30 million acne patients seek treatment in the U.S. each year - - DMT310, if approved, could be the first once-weekly topical produ...
Dermata Therapeutics Announces Exercise of Warrants for $2.66 Million in Gross Proceeds Priced At-the-Market Under Nasdaq Rules
SAN DIEGO, CA / ACCESSWIRE / May 17, 2024 / Dermata Therapeutics, Inc. (Nasdaq:DRMA)(Nasdaq:DRMAW) ("Dermata," or the "Company"), a late-stage biotechnology company focused on the treatment of medical...